|Bid||4.900 x 1400|
|Ask||4.910 x 2900|
|Day's Range||4.8800 - 5.0300|
|52 Week Range||3.6400 - 6.3000|
|Beta (3Y Monthly)||2.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.67|
Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.
Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.
Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.
Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.
Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.
Horizon Pharma's Ravicti Oral Liquid gets FDA approval to expand the age range to include infants younger than two months, living with a urea cycle disorder.
If you want to know who really controls Inovio Pharmaceuticals, Inc. (NASDAQ:INO), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk Read More...
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
Inovio Pharmaceuticals, Inc. (INO) announced today the dosing of the first patient in a Phase 2 combination trial to evaluate MedImmune’s MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination with durvalumab targeting a broad array of cancers associated with the human papilloma virus (HPV). This open-label trial funded by MedImmune, the global biologics research and development arm of AstraZeneca, is sponsored by noted cancer researcher Dr. Michael Frumovitz, MD, MPH, of the MD Anderson Cancer Center in Houston, Texas, where the trial will be conducted as part of MD Anderson’s “Moon Shot” cancer initiative.
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Emergent BioSolutions (EBS) and partner Valneva present positive data from an early-stage study on the Zika vaccine candidate, VLA1601.
Inovio Pharmaceuticals, Inc. (INO) made strategic leadership appointments in preparation for the commercialization of its lead asset and further development of its pipeline of immunotherapies and vaccines for cancer and challenging infectious diseases.
Inovio (INO) delivered earnings and revenue surprises of 15.63% and -9.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
PLYMOUTH MEETING, Pa., Nov. 08, 2018 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA.
Inovio Pharmaceuticals Inc (NASDAQ:INO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is INO Read More...
PLYMOUTH MEETING, Pa., Nov. 05, 2018 -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the Company will participate in the following upcoming investment.